Beyond statins: lipid management to reduce cardiovascular risk (Q38100747)

28 August 2017

Beyond statins: lipid management to reduce cardiovascular risk (English)

1 reference

28 August 2017

Robert N Schuck

1

1 reference

28 August 2017

Philip M Mendys

series ordinal

2

1 reference

28 August 2017

Ross J Simpson

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

18 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

33

1 reference

28 August 2017

7

1 reference

28 August 2017

754-764

1 reference

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

28 August 2017

1 reference

Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease

21 January 2018

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States

21 January 2018

1 reference

Progress and challenges in translating the biology of atherosclerosis

21 January 2018

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem

21 January 2018

1 reference

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction

21 January 2018

1 reference

Mechanism of action of niacin

21 January 2018

1 reference

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

21 January 2018

1 reference

Analyses of cancer data from three ezetimibe trials

21 January 2018

1 reference

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

21 January 2018

1 reference

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

21 January 2018

1 reference

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

21 January 2018

1 reference

Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate

21 January 2018

1 reference

Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists

21 January 2018

1 reference

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia

21 January 2018

1 reference

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

CHOLESTYRAMINE RESIN THERAPY FOR HYPERCHOLESTEREMIA: CLINICAL AND METABOLIC STUDIES.

21 January 2018

1 reference

Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortality

21 January 2018

1 reference

Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives

21 January 2018

1 reference

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

n-3 fatty acids and cardiovascular events after myocardial infarction

21 January 2018

1 reference

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

21 January 2018

1 reference

Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis

21 January 2018

1 reference

Safety of aggressive lipid management

21 January 2018

1 reference

Evidence-based management of statin myopathy.

21 January 2018

1 reference

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1268

1 reference

28 August 2017

1 reference